Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?

Top-Thema

12:32 Uhr
Market Insight: Erleichterungsrallye nach Frankreich Wahl

EXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Files in U.S. District Court to Recover Losses Suffered by Investors in Regulus Therapeutics Inc. -Lead Plaintiff Deadline of April 3, 2017

Dienstag, 14.02.2017 17:05 von

PR Newswire

NEW YORK, Feb. 14, 2017 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc. ("Regulus") (NASDAQ: RGLS) between February 17, 2016 and January 27, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Jin v. Regulus Therapeutics Inc., et al. (Case No. 17cv0267 LAB JMA) in the USDC for the Southern District of New York. To get more information go to:

http://www.zlk.com/pslra/regulus-therapeutics

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the Class Period, Regulus made materially false and/or misleading statements and/or failed to disclose that: (i) RG-101 was not safe and well tolerated by all patients in the ongoing studies, (ii) cases of serious adverse events ("SAE") were discovered, (iii) the SAEs were proof of serious concerns about the safety profile of RG-101, (iv) Regulus would likely need to produce extensive data to the U.S Food and Drug Administration ("FDA") to continue clinical trials of RG-101, and (v) as a result of the foregoing, Defendants' statements about Regulus' business and prospects, were false and misleading and/or lacked a reasonable basis.

Take Action: if you suffered a loss in Regulus you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/expanded-class-period-levi--korsinsky-llp-files-in-us-district-court-to-recover-losses-suffered-by-investors-in-regulus-therapeutics-inc-lead-plaintiff-deadline-of-april-3-2017-300407072.html

SOURCE Levi & Korsinsky, LLP